Navigation Links
Sofinnova Partners Leads Investment Round in CoAxia
Date:6/22/2009

Funding of Stroke Company Exemplifies Firm's Strategy in the Field of Medical Device

PARIS and MINNEAPOLIS, June 22 /PRNewswire/ -- Sofinnova Partners of Paris, France today announced having led a $21.5M financing in Minneapolis based medical device company CoAxia. The round also included participation from previous major investors Affinity Capital Management, Baird Venture Partners, Canaan Ventures Partners, Johnson and Johnson Development Corporation, and Prism Ventureworks.

CoAxia is a company developing NeuroFlo(TM), a device providing perfusion augmentation developed for the treatment of ischemic stroke. The purpose of this Series D financing is to provide sufficient funds for CoAxia to complete its SENTIS pivotal trial, and to submit results to the US FDA. In addition, the funds will allow further investigation of NeuroFlo in combination with a variety of stroke devices and drugs, and initiation of marketing.

Antoine Papiernik, Managing Partner at Sofinnova Partners commented: "Sofinnova is pleased to have led this financing round in CoAxia. We have long been interested in treatment opportunities in ischemic stroke, given the very large, global, untreated population. We had been following CoAxia's progress for many years, already considered investing five years ago, but we felt today was for us the right time to get involved. We find the NeuroFlo technique very compelling, given its ease of use, excellent safety profile and impressive early clinical results. If the SENTIS trial is successful, we believe that NeuroFlo has the potential to become a standard of care. We are very impressed with the strength of CoAxia's operating team, with whom we have interacted for many years, and are convinced that they can continue to deliver on the NeuroFlo potential. I look forward to joining CoAxia's Board of Directors for this exciting period ahead."

CoAxia President & CEO Andrew M. Weiss stated, "We are excited to have attracted Sofinnova Partners to lead this round, and to have continued support from our current investors: Affinity, Baird, Canaan, JJDC & Prism. Despite the difficult financial environment, we are pleased to have raised a sizeable, and oversubscribed, financing round. These funds will provide the resources to finalize our pivotal trial and demonstrate safety and efficacy. Looking forward, with Sofinnova's experience in financing medical device companies to successful exits, we believe that we are now well positioned for trial completion, PMA submission and initiation of sales and marketing."

Sofinnova, since its founding in 1972, has had a strategy to fund medical device and biopharmaceutical companies developing breakthrough technologies and products dedicated to large unmet clinical needs. Not unlike its landmark investment in Corevalve (recently sold to Medtronic), for which Sofinnova Partners was the founding and largest investor, this CoAxia investment is made in a company that has the potential to revolutionize its field.

Sofinnova Partners is an independent venture capital firm based in Paris, France that specializes in investments in early stage companies and corporate spin-offs in life sciences and technology. Since 1972, the firm has financed over 450 companies, many of which have gone public or have been acquired, and currently manages over euro 1 billion in assets. Sofinnova's experienced team and hands-on approach in nurturing and supporting portfolio companies from initial financing to successful exit have created market leaders and multiplied revenues. www.sofinnova.fr

CoAxia, Inc. is a venture-backed, privately held, clinical-stage company providing perfusion augmentation therapies to improve outcomes for patients with cerebral ischemia resulting from stroke, vasospasm and other conditions. In addition to the SENTIS, Flo24 and FASTFlo trials for ischemic stroke, CoAxia's NeuroFlo(TM) & FloControl(TM) devices have been approved by the US FDA via Humanitarian Device Exemption for the treatment of cerebral vasospasm, have received US FDA 510(k) clearance, and have secured the CE Mark for cerebral perfusion augmentation.


'/>"/>
SOURCE CoAxia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
5. AtriCure to Present at Roth Capital Partners 2007 New York Conference
6. MDS to Present at Thomas Weisel Partners Healthcare Conference
7. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
8. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. National Patient Safety Foundation Partners with Vocera Communications
11. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... My T Chai, a South African company that creates a number of ... a popular website specializing in sales of nutritional products. , Chai tea is ... It spread across Asia and Africa quickly, and today recipes vary from region to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As a former ... a thousand words. The good news for single women is that she put all ... is available on April 25th. Joan's insight, personal experiences and sparkling sense of humor ...
(Date:4/24/2017)... ... April 24, 2017 , ... A new global study of ... student well-being has seriously declined. "When disenfranchised youth from the heart of our ... State to turn the historic multi-ethnic and multi-religious powerhouses of the Middle East ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami ... attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant ... will present its annual Global Symposium at the Fontainebleau Hotel located in Miami ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
Breaking Medicine Technology: